Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRGX CARGO Therapeutics	$4.49 +0.2%	$4.45	$3.00 ▼ $25.45	$216.67M	0.3	1.78 million shs	1.25 million shs
CYCC Cyclacel Pharmaceuticals	$8.78 -2.1%	$8.38	$3.08 ▼ $597.60	$14.22M	0.08	5.21 million shs	227,767 shs
NAGE Niagen Bioscience	$9.73 +1.2%	$11.77	$2.69 ▼ $14.69	$766.43M	2.12	1.29 million shs	1.84 million shs
RCKT Rocket Pharmaceuticals	$2.86 -7.4%	$2.95	$2.19 ▼ $22.01	$329.97M	0.65	3.07 million shs	3.24 million shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRGX CARGO Therapeutics	+0.22%	0.00%	-2.39%	+11.69%	-67.56%
CYCC Cyclacel Pharmaceuticals	-2.12%	-9.67%	+135.39%	+130.36%	-97.54%
NAGE Niagen Bioscience	+1.25%	+7.63%	-19.72%	+8.72%	+251.26%
RCKT Rocket Pharmaceuticals	-7.44%	-4.35%	-10.63%	-58.97%	-84.87%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRGX CARGO Therapeutics	2.4704 of 5 stars	2.9	0.0	0.0	3.3	1.7	1.3
CYCC Cyclacel Pharmaceuticals	0.5426 of 5 stars	0.0	2.0	0.0	2.1	2.5	0.0
NAGE Niagen Bioscience	1.3286 of 5 stars	3.5	0.0	0.0	1.9	0.0	0.0
RCKT Rocket Pharmaceuticals	4.8423 of 5 stars	4.2	4.0	4.7	1.7	4.2	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRGX CARGO Therapeutics	1.86	Reduce	$15.40	242.98% Upside
CYCC Cyclacel Pharmaceuticals	2.00	Hold	N/A	N/A
NAGE Niagen Bioscience	3.00	Buy	$13.22	35.87% Upside
RCKT Rocket Pharmaceuticals	2.35	Hold	$16.40	473.43% Upside

Current Analyst Ratings Breakdown

Latest CRGX, RCKT, CYCC, and NAGE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	RCKT Rocket Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$10.00 ➝ $8.00
7/25/2025	RCKT Rocket Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $10.00
7/25/2025	RCKT Rocket Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$9.00 ➝ $4.00
7/24/2025	RCKT Rocket Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$17.00 ➝ $12.00
7/24/2025	RCKT Rocket Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
7/8/2025	CRGX CARGO Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$3.70 ➝ $5.00
6/17/2025	RCKT Rocket Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $5.00
6/10/2025	NAGE Niagen Bioscience	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$13.00 ➝ $16.00
6/6/2025	NAGE Niagen Bioscience	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $23.00
6/3/2025	RCKT Rocket Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$34.00 ➝ $11.00
5/30/2025	RCKT Rocket Pharmaceuticals	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ In-Line	$5.00

(Data available from 8/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRGX CARGO Therapeutics	N/A	N/A	N/A	N/A	$4.91 per share	N/A
CYCC Cyclacel Pharmaceuticals	$40K	346.81	N/A	N/A	($58.87) per share	-0.15
NAGE Niagen Bioscience	$99.60M	7.79	$0.06 per share	162.47	$0.80 per share	12.16
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	$5.08 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRGX CARGO Therapeutics	-$167.50M	-$4.62	N/A	N/A	N/A	N/A	-43.21%	-37.26%	8/11/2025 (Estimated)
CYCC Cyclacel Pharmaceuticals	-$11.21M	-$839.58	N/A	∞	N/A	N/A	-3,648.09%	-155.99%	8/13/2025 (Estimated)
NAGE Niagen Bioscience	$8.55M	$0.17	46.34	∞	N/A	15.24%	23.12%	15.53%	N/A
RCKT Rocket Pharmaceuticals	-$258.75M	-$2.63	N/A	N/A	N/A	N/A	-63.19%	-54.69%	N/A

Latest CRGX, RCKT, CYCC, and NAGE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	RCKT Rocket Pharmaceuticals	-$0.57	-$0.59	-$0.02	-$0.62	$4.36 million	N/A
8/6/2025	Q2 2025	NAGE Niagen Bioscience	$0.02	$0.04	+$0.02	$0.04	$28.55 million	$31.12 million
5/13/2025	Q1 2025	RCKT Rocket Pharmaceuticals	-$0.58	-$0.56	+$0.02	N/A	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRGX CARGO Therapeutics	N/A	N/A	N/A	N/A	N/A
CYCC Cyclacel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NAGE Niagen Bioscience	N/A	N/A	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRGX CARGO Therapeutics	N/A	12.37	6.30
CYCC Cyclacel Pharmaceuticals	N/A	5.60	5.60
NAGE Niagen Bioscience	N/A	3.88	3.12
RCKT Rocket Pharmaceuticals	0.05	9.19	9.19

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRGX CARGO Therapeutics	93.16%
CYCC Cyclacel Pharmaceuticals	23.58%
NAGE Niagen Bioscience	15.41%
RCKT Rocket Pharmaceuticals	98.39%

Insider Ownership

Company	Insider Ownership
CRGX CARGO Therapeutics	2.92%
CYCC Cyclacel Pharmaceuticals	51.20%
NAGE Niagen Bioscience	9.39%
RCKT Rocket Pharmaceuticals	24.76%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRGX CARGO Therapeutics	116	48.36 million	44.76 million	N/A
CYCC Cyclacel Pharmaceuticals	14	1.58 million	773,000	Optionable
NAGE Niagen Bioscience	120	79.75 million	71.37 million	N/A
RCKT Rocket Pharmaceuticals	240	106.79 million	80.35 million	Optionable

CRGX, RCKT, CYCC, and NAGE Headlines

Recent News About These Companies

Class Action Filed Against Rocket Pharmaceuticals, Inc. (RCKT) Seeking Recovery for Investors – Contact Levi & Korsinsky

August 8 at 4:01 PM | globenewswire.com

DEADLINE NEXT WEEK: Berger Montague Advises Rocket Pharmaceuticals (NASDAQ: RCKT) Investors to Contact the Firm Before August 11, 2025

August 8 at 2:16 PM | prnewswire.com

Deadline Soon: Rocket Pharmaceuticals, Inc. (RCKT) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

August 8 at 12:38 PM | businesswire.com

Rocket Pharmaceuticals, Inc. (RCKT) Faces Securities Class Action Amid Protocol Change and FDA's Clinical Hold on Gene Therapy Trial – Hagens Berman

August 8 at 9:02 AM | globenewswire.com

August 11, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against RCKT

August 8 at 8:45 AM | prnewswire.com

MONDAY INVESTOR DEADLINE: Robbins Geller Rudman & Dowd Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

August 7 at 7:45 PM | globenewswire.com

Investors in Rocket Pharmaceuticals, Inc. Should Contact The Gross Law Firm Before August 11, 2025 to Discuss Your Rights – RCKT

August 7 at 4:33 PM | globenewswire.com

Rocket Pharmaceuticals, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. August 11, 2025 Deadline to file Lead Plaintiff Motion.

August 7 at 4:17 PM | globenewswire.com

RCKT DEADLINE: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important August 11 Deadline in Securities Class Action – RCKT

August 7 at 3:40 PM | globenewswire.com

Deadline Alert: Rocket Pharmaceuticals, Inc. (RCKT) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit

August 7 at 2:32 PM | globenewswire.com

Lost Money on Rocket Pharmaceuticals, Inc. ...

August 7 at 9:22 AM | gurufocus.com

Lost Money on Rocket Pharmaceuticals, Inc.(RCKT)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm

August 7 at 8:45 AM | prnewswire.com

Rocket Pharmaceuticals, Inc. (RCKT) Faces Securities Class Action Amid Protocol Change and ...

August 6 at 6:13 PM | gurufocus.com

Rocket Pharmaceuticals, Inc. (RCKT) Faces Securities Class Action Amid Protocol Change and FDA's Clinical Hold on Gene Therapy Trial – Hagens Berman

August 6 at 5:44 PM | globenewswire.com

RCKT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

August 6 at 4:00 PM | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Rocket Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - RCKT

August 6 at 10:00 AM | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Rocket Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - RCKT

August 6 at 10:00 AM | prnewswire.com

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Shares Purchased by Westfield Capital Management Co. LP

August 6 at 5:39 AM | marketbeat.com

Rocket Pharmaceuticals, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. August 11, 2025 Deadline to file Lead Plaintiff Motion

August 5, 2025 | globenewswire.com

Shareholders of Rocket Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before August 11, 2025 to Discuss Your Rights – RCKT

August 5, 2025 | globenewswire.com

DEADLINE APPROACHING: Berger Montague Advises Rocket Pharmaceuticals (NASDAQ: RCKT) Investors to Inquire About a Securities Fraud Class Action by August 11, 2025

August 5, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRGX, RCKT, CYCC, and NAGE Company Descriptions

CARGO Therapeutics NASDAQ:CRGX

$4.49 +0.01 (+0.22%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$4.49 0.00 (0.00%)

As of 08/8/2025 05:46 PM Eastern

CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.

Cyclacel Pharmaceuticals NASDAQ:CYCC

$8.78 -0.19 (-2.12%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$8.83 +0.05 (+0.57%)

As of 08/8/2025 07:59 PM Eastern

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.

Niagen Bioscience NASDAQ:NAGE

$9.73 +0.12 (+1.25%)

As of 08/8/2025 04:00 PM Eastern

Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.

Rocket Pharmaceuticals NASDAQ:RCKT

$2.86 -0.23 (-7.44%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$2.88 +0.02 (+0.70%)

As of 08/8/2025 07:46 PM Eastern

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time